GHK-Cu's story wandered well beyond skin.
The backstory gets more adventurous here: lungs, gut and memory. These are research leads, and their animal labels need to travel with them.
Lungs in a mouse experiment
Researchers tested GHK-Cu in mice with smoke-related lung damage. They reported less inflammation and oxidative stress, meaning chemical strain on cells. It's an interesting finding in that model. It doesn't establish a treatment for someone with emphysema.
A model lets researchers study selected parts of an illness. It can't carry every part of a person's health history. The experiment can help choose the next question without answering the care question. I want the mouse label beside the result, where it can actually affect how we read it.
The gut finding also came from mice
A colitis study tested GHK-Cu in mice and cells. Colitis means inflammation of the colon. Researchers reported improvements in experimental illness measures and proteins that help maintain the gut barrier. The mouse illness was brought on chemically; this wasn't a trial in people.
The material was delivered into the mice's stomachs. Retelling it as support for human injections would change both the species and the route. It also leaves unanswered how GHK-Cu would compare with established care for ulcerative colitis. A promising animal result doesn't supply that comparison.
The animal label belongs beside the exciting part, every time.
Memory, through the nose, in older mice
In an aging-mouse memory study, GHK-Cu given through the nose improved some learning and spatial-memory results. The title uses the shorter name GHK, while the study describes GHK-Cu. The linked version is a preprint: it hadn't been through peer review in that form.
That's a lot to leave out of a memory headline: mice, nasal delivery and an early report. The finding doesn't establish better memory in people. It doesn't establish an injection benefit either. Those questions would need studies designed to answer them, rather than a more exciting retelling of this one.
Three leads don't add up to one treatment
These studies ask different questions about different problems. Adding them together doesn't produce several confirmations of one human benefit. Their value is in showing researchers where to look next. The gene chapter follows another route from a lab finding to a much larger reputation.
Safety remains a separate gap. FDA notes possible immune reactions and limited human information for injectable GHK-Cu. The concern includes possible peptide clumping and impurities. The care questions explain why encouraging animal work doesn't settle that issue.